The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 350:2719-2720 June 24, 2004 Number 26
NextNext

Hepatitis B

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Ganem, D.
-PubMed Citation
To the Editor: Ganem and Prince (March 11 issue)1 state that sustained remission of hepatitis B virus (HBV) infection is infrequently achieved by current treatment regimens. We recently showed that sustained remission is present after a response (loss of hepatitis B e antigen [HBeAg]) to interferon alfa.2 After long-term follow-up, patients who had a response to interferon alfa had a loss of hepatitis B surface antigen (HBsAg) and HBV DNA, as demonstrated by the polymerase chain reaction, significantly more often than those without a response (loss of HBsAg, 52 percent vs. 9 percent; loss of HBV DNA, 70 percent vs. . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.